Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study designed to evaluate the safety, tolerability, and effect of a single, rising dose of intravenous AL-208, followed by a placebo-controlled, double-blind, parallel-group evaluation of a single dose of AL-208, on mild cognitive impairment following coronary artery bypass graft surgery

Next Previous
X
Search
Trial Profile

A phase II study designed to evaluate the safety, tolerability, and effect of a single, rising dose of intravenous AL-208, followed by a placebo-controlled, double-blind, parallel-group evaluation of a single dose of AL-208, on mild cognitive impairment following coronary artery bypass graft surgery

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Davunetide (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Sep 2008 Planned end date changed from 1 Mar 2008 to 1 Mar 2008.
    • 11 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Top-line results expected in third quater 2008 according to Allon Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top